Last week, Sysnav Healthcare participated in the 2025 Annual NEALS Meeting in Florida.
In collaboration with Dr. James Berry’s team at Massachusetts General Hospital, our team presented a poster highlighting how digital endpoints, such as the SV95C, can sensitively and reliably quantify the progression of motor impairment in people living with ALS.
The findings highlight the potential of digital biomarkers to provide objective, precise measures of disease progression in ALS.
We extend our sincere thanks to the NEALS Consortium for organizing this event and for fostering a vibrant ALS research and clinical ecosystem.
The Sysnav team came away inspired by the innovative science, emerging therapeutic approaches, and the shared commitment across the ecosystem to improving outcomes for people living with ALS.
You can access the poster here.
